Ceftolozane/tazobactam sensitivity patterns in Pseudomonas aeruginosa isolates recovered from sputum of cystic fibrosis patients

doi:10.1016/j.diagmicrobio.2018.05.002

Diagnostic Microbiology and Infectious Disease

Volume 92, Issue 1, September 2018, Pages 75-77

https://doi.org/10.1016/j.diagmicrobio.2018.05.002 Get rights and content

Highlights

•
Pan–drug-resistant or extended drug-resistant Pseudomonas is a growing problem in the CF population.
•
Ceftolozane/tazobactam is a new antibiotic agent that can be used in carefully selected CF patients during a pulmonary exacerbation.
•
One major question remains: how should physicians use ceftolozane/tazobactam in treating CF patients while at the same time trying to remain good stewards of antibiotics?

Abstract

Ceftolozane/tazobactam is a combination intravenous antibiotic with potentially important activity against drug-resistant Gram-negative organisms. Ceftolozane/tazobactam's in vitro activity was evaluated in 30 samples collected from 23 adult cystic fibrosis patients with extended and pan-resistant Pseudomonas aeruginosa in 2015. Testing results demonstrated that 30% of the isolates were susceptible,13% were intermediate, and 57% were resistant. This suggests that ceftolozane/tazobactam may be a useful antibiotic in carefully selected, multidrug-resistant Pseudomonas isolates.

Section snippets

Acknowledgments

We would like to thank the University of Texas Southwestern microbiology laboratory at Clements University Hospital and Cubist Reference Laboratory in Westlake, OH, for testing these samples.

Disclosures:

James Finklea: Gilead Pharmaceuticals consultant.

Karen Lowe has nothing to disclose.

Raksha Jain has nothing to disclose.

Jane Ciurca has nothing to disclose.

Francesca Lee has nothing to disclose.

Jade Le has nothing to disclose.

Rita Hollaway has nothing to disclose.

The study was presented at the

References (15)

C.H. Chen et al.
Different bacteriology and prognosis of thoracic empyemas between patients with chronic and end-stage renal disease
Chest
(2007)
J.L. Kuti et al.
Microbiological activity of ceftolozane/tazobactam, ceftazidime, meropenem, and piperacillin/tazobactam against Pseudomonas aeruginosa isolated from children with cystic fibrosis
Diagn Microbiol Infect Dis
(2015)
A.P. Magiorakos et al.
Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance
Clin Microbiol Infect
(2012)
A.L. Smith et al.
Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis
Chest
(2003)
F.M. Wagenlehner et al.
Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI)
Lancet
(2015)
ClinicalTrials.gov
Trial number MK-7625A-008
(2018)
Cystic Fibrosis Foundation, C
Patient registry annual data report
(2014)

There are more references available in the full text version of this article.

Cited by (0)

View full text

Antimicrobial Susceptibility StudyCeftolozane/tazobactam sensitivity patterns in Pseudomonas aeruginosa isolates recovered from sputum of cystic fibrosis patients

Highlights

Abstract

Section snippets

Acknowledgments

Chest

Diagn Microbiol Infect Dis

Clin Microbiol Infect

Chest

Lancet

Trial number MK-7625A-008

Patient registry annual data report

Antimicrobial Susceptibility Study
Ceftolozane/tazobactam sensitivity patterns in Pseudomonas aeruginosa isolates recovered from sputum of cystic fibrosis patients